keyword
MENU ▼
Read by QxMD icon Read
search

Varenicline

keyword
https://www.readbyqxmd.com/read/29666043/mobile-app-usage-patterns-of-patients-prescribed-a-smoking-cessation-medicine-prospective-observational-study
#1
Marianna Bruno, Marcia Wright, Christine L Baker, Birol Emir, Eric Carda, Michelle Clausen, Catherine Sigler, Aanal Patel
BACKGROUND: Cigarette smoking is the leading preventable cause of death and is responsible for more than 480,000 deaths per year in the United States. Smoking cessation is challenging for many patients. Regardless of available treatment options, most quit attempts are unaided, and it takes multiple attempts before a patient is successful. With the ever-increasing use of smartphones, mobile apps hold promise in supporting cessation efforts. This study evaluates the ease of use and user satisfaction with the Pfizer Meds app to support smoking cessation among patients prescribed varenicline (Chantix)...
April 17, 2018: JMIR MHealth and UHealth
https://www.readbyqxmd.com/read/29664530/-clinical-practice-guidelines-for-smoking-cessation
#2
María Paz Corvalán B, Leonardo Véjar M, Claudia Bambs S, Juana Pavié G, Mónica Zagolin B, Jaime Cerda L
Considering that a high proportion of the Chilean general population smokes, the Chilean Society of Respiratory Diseases in collaboration with the Chilean Societies of Cardiology and, Endocrinology and Diabetes, formed an interdisciplinary group, who issued a set of recommendations for the treatment of the smoker, methodologically advised by experts. These interventions should be prioritized in high-risk groups. Methods The panel elaborated and graded the recommendations following the GRADE methodology. To assess the effect of each intervention, systematic reviews and randomized clinical trials were identified...
November 2017: Revista Médica de Chile
https://www.readbyqxmd.com/read/29661542/helping-patients-with-esrd-and-earlier-stages-of-ckd-to-quit-smoking
#3
REVIEW
Perry Formanek, Elizabeth Salisbury-Afshar, Majid Afshar
Among the many adverse effects of tobacco exposure is the increased risk for progression of kidney disease. Individuals with chronic kidney disease (CKD), who already face increased cardiovascular event rates compared to the general population, are at even greater risk if they smoke. Despite these risks and the increased focus on smoking cessation in the general population in recent years, national guidelines have not specifically targeted individuals with CKD. There are similarly sparse data specific to individuals with CKD regarding the safety and efficacy of evidence-based smoking cessation modalities...
April 13, 2018: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
https://www.readbyqxmd.com/read/29650283/-interventions-for-smoking-cessation-in-2018
#4
REVIEW
J Abdul-Kader, G Airagnes, S D'almeida, F Limosin, A-L Le Faou
Smoking cessation treatments have been proved effective to stop smoking. For pharmacological treatments, nicotine replacement therapies (NRT) as well as bupropion allow to increase 6 month-abstinence rates by more than 80% in comparison with placebo while varenicline prescription doubles success rates in the same conditions. These results mean that for 10 smokers who quit with placebo, 18 are expected to quit with NRT or bupropion and 28 are expected to quit with varenicline. Varenicline is 50% more effective than nicotine patch and 70% more effective than nicotine gum...
April 9, 2018: Revue de Pneumologie Clinique
https://www.readbyqxmd.com/read/29621993/cholinergic-receptor-nicotinic-alpha-5-subunit-polymorphisms-are-associated-with-smoking-cessation-success-in-women
#5
Paulo Roberto Xavier Tomaz, Juliana Rocha Santos, Jaqueline Scholz, Tânia Ogawa Abe, Patrícia Viviane Gaya, André Brooking Negrão, José Eduardo Krieger, Alexandre Costa Pereira, Paulo Caleb Júnior Lima Santos
BACKGROUND: The identification of variants in the nicotinic acetylcholine receptor (nAChR) subunit genes associated with smoking phenotypes are increasingly important for prevention and treatment of nicotine dependence. In the context of personalized medicine, the aims of this study were to evaluate whether cholinergic receptor nicotinic alpha 2 (CHRNA2), cholinergic receptor nicotinic alpha 3 (CHRNA3), cholinergic receptor nicotinic alpha 5 (CHRNA5) and cholinergic receptor nicotinic beta 3 (CHRNB3) polymorphisms were associated with nicotine dependence severity, and to investigate possible pharmacogenetics markers of smoking cessation treatment...
April 5, 2018: BMC Medical Genetics
https://www.readbyqxmd.com/read/29604474/varenicline-for-smoking-reduction-in-smokers-not-yet-ready-to-quit-a-double-blind-proof-of-concept-randomized-clinical-trial
#6
Marc L Steinberg, Shou-En Lu, Jill M Williams
BACKGROUND: Varenicline has demonstrated efficacy for quitting smoking. Its agonist and antagonist effects suggest that it would be efficacious for reducing cigarettes per day in smokers not yet ready to quit. OBJECTIVES: To conduct a proof-of-concept placebo-controlled randomized clinical trial of varenicline for smokers willing to reduce, but not quit smoking. METHODS: Smokers (N = 53) were randomized to receive 28-days of varenicline plus brief counseling or 28-days of placebo plus brief counseling...
March 26, 2018: Addictive Behaviors
https://www.readbyqxmd.com/read/29587555/discovery-and-development-of-varenicline-for-smoking-cessation
#7
Chloe J Jordan, Zheng-Xiong Xi
Tobacco use causes one premature death every six seconds. Current smoking cessation aids include nicotine replacement therapies, bupropion, and varenicline. Although more than 70% of smokers express a desire to quit, fewer than 3% remain abstinent for more than one year, highlighting a critical need for more efficacious smoking cessation treatments. Areas covered: The authors discuss the rationale, preclinical and clinical development of varenicline for smoking cessation. They cover the formulation of varenicline as a partial agonist at α4 β2 receptors, the primary neural substrate for nicotine reward...
March 28, 2018: Expert Opinion on Drug Discovery
https://www.readbyqxmd.com/read/29581161/smoking-abstinence-1-year-after-acute-coronary-syndrome-follow-up-from-a-randomized-controlled-trial-of-varenicline-in-patients-admitted-to-hospital
#8
Sarah B Windle, Payam Dehghani, Nathalie Roy, Wayne Old, François R Grondin, Iqbal Bata, Ayman Iskander, Claude Lauzon, Nalin Srivastava, Adam Clarke, Daniel Cassavar, Danielle Dion, Herbert Haught, Shamir R Mehta, Jean-François Baril, Charles Lambert, Mina Madan, Beth L Abramson, Mark J Eisenberg
BACKGROUND: Patients who continue to smoke after acute coronary syndrome are at increased risk of reinfarction and death. We previously found use of varenicline to increase abstinence 24 weeks after acute coronary syndrome; here we report results through 52 weeks. METHODS: The EVITA trial was a multicentre, double-blind, randomized, placebo-controlled trial of varenicline for smoking cessation in patients admitted to hospital with acute coronary syndrome. Participants were randomly assigned (1:1) to receive varenicline or placebo for 12 weeks, in conjunction with low-intensity counselling...
March 26, 2018: CMAJ: Canadian Medical Association Journal, Journal de L'Association Medicale Canadienne
https://www.readbyqxmd.com/read/29579233/systematic-review-and-meta-analysis-to-assess-the-safety-of-buproprion-and-varenicline-in-pregnancy
#9
Emily Turner, Matthew Jones, Luis R Vaz, Tim Coleman
Introduction: Smoking in pregnancy is a substantial public health issue, but, apart from nicotine replacement therapy (NRT), pharmacological therapies are not generally used to promote cessation. Bupropion and varenicline are effective cessation methods in non-pregnant smokers and this systematic review investigates their safety in pregnancy. Methods: We searched MEDLINE, EMBASE, CINAHL and PsychINFO databases for studies of any design reporting pregnancy outcomes after bupropion or varenicline exposure...
March 22, 2018: Nicotine & Tobacco Research: Official Journal of the Society for Research on Nicotine and Tobacco
https://www.readbyqxmd.com/read/29578832/pilot-randomized-trial-of-an-automated-smoking-cessation-intervention-via-mobile-phone-text-messages-as-an-adjunct-to-varenicline-in-primary-care
#10
Jessica M Yingst, Susan Veldheer, Shari Hrabovsky, Erin Hammett, James Nicholson, Arthur Berg, Jonathan Foulds
OBJECTIVE: Varenicline is a safe and effective aid to smoking cessation but most trials have involved frequent visits or intensive behavioral support unlike that typically provided in primary care. The current study examined if motivational text messages, sent via cellphone, would increase quit rates in smokers being treated with varenicline and 3 brief sessions in a family practice setting. METHODS: This study was a randomized controlled, parallel-group smoking cessation trial...
March 26, 2018: Journal of Health Communication
https://www.readbyqxmd.com/read/29538542/evaluation-of-smoking-cessation-treatment-initiated-during-hospitalization-in-patients-with-heart-disease-or-respiratory-disease
#11
Thaís Garcia, Sílvia Aline Dos Santos Andrade, Angélica Teresa Biral, André Luiz Bertani, Laura Miranda de Oliveira Caram, Talita Jacon Cezare, Irma Godoy, Suzana Erico Tanni
OBJECTIVE: To evaluate the effectiveness of a smoking cessation program, delivered by trained health care professionals, in patients hospitalized for acute respiratory disease (RD) or heart disease (HD). METHODS: Of a total of 393 patients evaluated, we included 227 (146 and 81 active smokers hospitalized for HD and RD, respectively). All participants received smoking cessation treatment during hospitalization and were followed in a cognitive-behavioral smoking cessation program for six months after hospital discharge...
January 2018: Jornal Brasileiro de Pneumologia: Publicaça̋o Oficial da Sociedade Brasileira de Pneumologia e Tisilogia
https://www.readbyqxmd.com/read/29532966/cost-effectiveness-of-alternative-smoking-cessation-scenarios-in-spain-results-from-the-equiptmod
#12
Marta Trapero-Bertran, Celia Muñoz, Kathryn Coyle, Doug Coyle, Adam Lester-George, Reiner Leidl, Bertalan Németh, Kei-Long Cheung, Subhash Pokhrel, Ángel Lopez-Nicolás
AIMS: To assess the cost-effectiveness of alternative smoking cessation scenarios from the perspective of the Spanish National Health Service (NHS). DESIGN: We used the European study on Quantifying Utility of Investment in Protection from Tobacco model (EQUIPTMOD), a Markov-based state transition economic model, to estimate the return on investment (ROI) of: (a) the current provision of smoking cessation services (brief physician advice and printed self-helped material + smoking ban and tobacco duty at current levels); and (b) four alternative scenarios to complement the current provision: coverage of proactive telephone calls; nicotine replacement therapy (mono and combo) [prescription nicotine replacement therapy (Rx NRT)]; varenicline (standard duration); or bupropion...
March 13, 2018: Addiction
https://www.readbyqxmd.com/read/29532538/estimates-of-costs-for-modelling-return-on-investment-from-smoking-cessation-interventions
#13
Marta Trapero-Bertran, Reiner Leidl, Celia Muñoz, Puttarin Kulchaitanaroaj, Kathryn Coyle, Maximilian Präger, Judit Józwiak-Hagymásy, Kei Long Cheung, Mickael Hiligsmann, Subhash Pokhrel
BACKGROUND AND AIMS: Modelling return on investment (ROI) from smoking cessation interventions requires estimates of their costs and benefits. This paper describes a standardized method developed to source both economic costs of tobacco smoking and costs of implementing cessation interventions for a Europe-wide ROI model [European study on Quantifying Utility of Investment in Protection from Tobacco model (EQUIPTMOD)]. DESIGN: Focused search of administrative and published data...
March 13, 2018: Addiction
https://www.readbyqxmd.com/read/29527846/smoking-cessation-strategies-targeting-specific-populations
#14
REVIEW
Eun Mi Chun
Quitting smoking helps smokers maintain their health and extend their lifespan by 10 or more years. Treatment strategies for smoking cessation should be tailored to individual smokers with special needs based on their specific circumstances. It is recommended that pregnant women adopt smoking cessation through counseling and behavioral interventions because the safety of medications has yet to be established. Counseling is the main strategy for smoking cessation in adolescents and nicotine replacement therapy can be used with caution in individuals with serious nicotine dependence...
March 7, 2018: Tuberculosis and Respiratory Diseases
https://www.readbyqxmd.com/read/29526275/smoking-cessation-in-patients-with-acute-coronary-syndrome
#15
REVIEW
Caroline Franck, Kristian B Filion, Mark J Eisenberg
Over 30% of the nearly 1 million North Americans hospitalized annually with an acute coronary syndrome (ACS) are smokers. Despite a substantially increased risk of morbidity and mortality, 2/3 of patients who quit smoking after ACS return to smoking within 1 year. To summarize the evidence of smoking cessation in patients hospitalized after ACS, we systematically reviewed all randomized controlled trials of pharmacologic and behavioral smoking cessation therapies in patients with ACS. In addition, we reviewed the clinical considerations surrounding the use of smoking cessation therapies, including their broad mechanisms of action and possible alternative treatments, including cardiac rehabilitation programs and electronic cigarettes...
February 6, 2018: American Journal of Cardiology
https://www.readbyqxmd.com/read/29508470/factors-associated-with-the-efficacy-of-smoking-cessation-treatments-and-predictors-of-smoking-abstinence-in-eagles
#16
Robert West, A Eden Evins, Neal L Benowitz, Cristina Russ, Thomas McRae, David Lawrence, Lisa St Aubin, Alok Krishen, Melissa C Maravic, Robert M Anthenelli
AIMS: To assess (1) how far the efficacies of front-line smoking cessation pharmacotherapies vary as a function of smoker characteristics and (2) associations between these characteristics and success of smoking cessation attempts. DESIGN: Prospective correlational study in the context of a double-blind randomized trial. The outcome was regressed individually onto each covariate after adjusting for treatment, and then a forward stepwise model constructed. Treatment moderator effects of covariates were tested by treatment × covariate interactions...
March 6, 2018: Addiction
https://www.readbyqxmd.com/read/29498158/preclinical-evidence-for-combining-the-5-ht-2c-receptor-agonist-lorcaserin-and-varenicline-as-a-treatment-for-nicotine-dependence
#17
Paul J Fletcher, Zhaoxia Li, Leo B Silenieks, Cam MacMillan, Ines DeLannoy, Guy A Higgins
Varenicline, a nicotinic acetylcholine receptor partial agonist, is used to treat nicotine dependence. Lorcaserin, a 5-HT2C receptor agonist has been approved in some countries to treat obesity. Based on preclinical and preliminary clinical evidence, lorcaserin may have potential to treat nicotine dependence. These experiments examined in rats the effects of combining varenicline (0.5 or 1 mg/kg) and lorcaserin (0.3, 0.6 and 1 mg/kg) on nicotine self-administration, reinstatement of nicotine seeking, responding for food and impulsive action...
March 2, 2018: Addiction Biology
https://www.readbyqxmd.com/read/29483658/muscarinic-m-5-receptors-modulate-ethanol-seeking-in-rats
#18
Alice E Berizzi, Christina J Perry, David M Shackleford, Craig W Lindsley, Carrie K Jones, Nicola A Chen, Patrick M Sexton, Arthur Christopoulos, Christopher J Langmead, Andrew J Lawrence
Despite the cost to both individual and society, alcohol use disorders (AUDs) remain a major health risk within society, and both relapse and heavy drinking are still poorly controlled with current medications. Here we demonstrate for the first time that a centrally active and selective negative allosteric modulator for the rat M5 muscarinic acetylcholine receptor (mAChR), ML375, decreases ethanol self-administration and attenuates cue-induced reinstatement of ethanol seeking in ethanol-preferring (iP) rats...
February 5, 2018: Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/29471329/effects-of-varenicline-depressive-symptoms-and-region-of-enrollment-on-smoking-cessation-in-depressed-smokers
#19
Neal Doran, Sarah Dubrava, Robert M Anthenelli
Introduction: Despite effective treatments, relapse to smoking remains a vexing global health problem. One predictor of relapse is depressive symptoms. Medications such as varenicline reduce withdrawal-related symptoms of depression, reducing relapse. This study examined whether varenicline moderated the effect of depressive symptoms on relapse, and whether this varied by region of enrollment. Methods: Adult smokers (n=525; 37% male) with past or current, stable major depressive disorder recruited from US (n=255), and European (n=270) sites participated in a randomized, double-blind cessation treatment trial including 12 weeks of varenicline or placebo, with 40-week non-treatment follow-up...
February 17, 2018: Nicotine & Tobacco Research: Official Journal of the Society for Research on Nicotine and Tobacco
https://www.readbyqxmd.com/read/29460494/the-effects-of-prescribing-varenicline-on-two-year-health-outcomes-an-observational-cohort-study-using-electronic-medical-records
#20
Neil M Davies, Gemma M J Taylor, Amy E Taylor, Timothy Jones, Richard M Martin, Marcus R Munafò, Frank Windmeijer, Kyla H Thomas
AIMS: To investigate whether smokers prescribed varenicline had lower risks of serious ill-health during the 4 years following treatment compared with those prescribed nicotine replacement therapy (NRT). DESIGN: Observational cohort study of electronic medical records. SETTING: A total of 370 UK general practices sampled from the Clinical Practice Research Datalink. PARTICIPANTS: A total of 126 718 patients aged 18 and over who were issued smoking cessation prescriptions between 1 September 2006 and 31 March 2014...
February 20, 2018: Addiction
keyword
keyword
77072
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"